Comparison of WHO Treatment of Acute Watery Diarrhea With or Without Probiotic (Bacillus Clausii) in Children
Launched by MUHAMMAD AAMIR LATIF · Mar 14, 2025
Trial Information
Current as of April 23, 2025
Completed
Keywords
ClinConnect Summary
Available literature regarding the use of probiotics is not conclusive and contains controversy, and local data is also scarce. Therefore, this study was planned to further explore the use of probiotics to furnish the local data. If significantly less mean duration of diarrhea is noted in the probiotic group, it will help to add probiotic bacillus clausii in routine treatment regimen recommended by WHO and to decrease costs associated with prolonged treatment. However, if otherwise results will be noted it will help to rule out use of probiotic bacillus clausii in children with acute diarrh...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Both genders
- • Aged 6 to 59 months
- • Suffering from acute watery diarrhea for ≤ 7 days
- Exclusion Criteria:
- • Children with blood in stool
- • With prior antibiotics use
- • Children under study with duration of stay more than 5 days
- • clinical signs of a coexisting acute systemic illness like pneumonia, sepsis, meningitis, severely malnourished
- • Immunocompromised children
- • Hypersensitivity to probiotics
- • With prior probiotic administration
Trial Officials
Talha Hassan
Principal Investigator
Children Hospital, Lahore, Pakistan
Muhammad Zeeshan
Study Director
Children Hospital, Lahore, Pakistan
About Muhammad Aamir Latif
Muhammad Aamir Latif is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a background in clinical research and a focus on innovative therapeutic solutions, he collaborates with healthcare professionals and institutions to design, implement, and oversee clinical trials. His expertise encompasses various therapeutic areas, ensuring adherence to regulatory standards and ethical guidelines. Through strategic partnerships and a patient-centered approach, Muhammad Aamir Latif aims to contribute significantly to the development of safe and effective treatments, fostering advancements in healthcare and enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lahore, Punjab, Pakistan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Related Blog Entries
View all
